Literature DB >> 1693890

Activation of the epileptic focus during intracarotid amobarbital test. Electrocorticographic registration via subdural electrodes.

A Hufnagel1, C E Elger, D K Böker, D B Linke, M Kurthen, L Solymosi.   

Abstract

During presurgical evaluation, bilateral intracarotid amobarbital tests were performed in 21 patients (42 tests) to establish the lateralization of cerebral speech dominance as well as memory function. All patients suffered from long-standing, medically intractable, complex partial seizures. Electrocorticographic recording during the investigation was carried out via bilaterally implanted subdural electrodes. The aim of the study was to assess amobarbital-induced effects on the primary epileptic focus, determined throughout presurgical evaluation. Following the application of amobarbital the primary epileptic focus was selectively activated in 10 and preferentially activated in 3 patients suffering from temporal lobe epilepsy. Specific responses of the primary epileptic focus consisted of: (i) induction of a spike-burst-suppression pattern, mainly in the mesio-basal aspects of the focal temporal lobe (n = 13); (ii) induction of spikes or sharp waves following contralateral intracarotid injection (n = 10); (iii) late induction of spikes or sharp waves following ipsilateral injection (n = 4); (iv) loss or marked reduction of drug-induced beta activity over the primary epileptic focus (n = 14) following ipsilateral or contralateral injection. In conclusion, electrocorticographic recording during the intracarotid amobarbital test contributes valuable information about the primary epileptic focus in a high proportion of patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693890     DOI: 10.1016/0013-4694(90)90132-4

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  3 in total

1.  A proposed modification of the Wada test for presurgical assessment in temporal lobe epilepsy.

Authors:  K Weissenborn; N Rückert; F Brassel; H Becker; H Dietz
Journal:  Neuroradiology       Date:  1996-07       Impact factor: 2.804

Review 2.  The clinical use of barbiturates in neurological disorders.

Authors:  M C Smith; B J Riskin
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.

Authors:  Robert Parker; Laura J Vella; Dylan Xavier; Ardeshir Amirkhani; Jimmy Parker; Jonathan Cebon; Mark P Molloy
Journal:  Front Oncol       Date:  2015-05-15       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.